DelveInsight’s ‘Liquid Biopsy in Cancer Diagnostics Market Insights, Competitive Landscape and Market Forecast-2026’ report delivers an in-depth understanding of liquid biopsy in cancer diagnostics and the historical and forecasted liquid biopsy in cancer diagnostics market trends in the US, EU5 (Germany, France, Spain, Italy, and the United Kingdom) and Japan.
The Liquid Biopsy in Cancer Diagnostics market report provides an overview of liquid biopsy in cancer diagnostics, applications of liquid biopsy in cancer diagnostics as well as its PEST Analysis. Additionally, the report provides insight on the liquid biopsy in cancer diagnostics market share of the individual liquid biopsy in cancer diagnostics, current and forecasted liquid biopsy in cancer diagnostics market size from 2018 to 2026, segmented by seven major markets. The report also covers the market drivers, market barriers and unmet needs to curate the best of opportunities and assesses underlying potential of the market.
Liquid Biopsy in Cancer Diagnostics Overview
Liquid biopsy is a method used to detect specific mutations in cell-free, circulating tumor DNA (ctDNA) from biofluids, such as plasma, urine, cerebrospinal fluid, and serum. Researchers around the world are actively investigating the use of ctDNA as a biomarker for profiling tumors, monitoring the effectiveness of therapies, assessing the clonal evolution of tumor cell populations, identifying resistance mechanisms, detecting early disease, and measuring minimal residual disease. Regardless of the specific use, liquid biopsy has the benefit of being non-invasive, and thus allowing samples to be easily collected for serial assessments. Mutation detection in liquid biopsy, however, is challenged by the extremely low fraction of ctDNA in the cell-free DNA (cfDNA) samples, making accurate detection of rare mutations difficult.
Study Period: 2018–2026
Geography Covered
• The US
• EU5 (Germany, France, Spain, Italy, and the United Kingdom)
• Japan
List of Companies:
Guardant Health, Qiagen, F. Hoffmann-La Roche AG, Inviata, ArcherDx, Bio-Techne., Resolution Bioscience & LabCorp., Personal Genome Diagnostics., Helio Health, Lucence, Foundation medicine Inc.., Biocept, Sysmex Corporation, Veridex LLC and Biodesix, among others.
This segment of the report provides a brief competitive analysis of liquid biopsy in cancer diagnostics, to help understand the competition in the market. It gives a comparative understanding of the products based on types.
Liquid Biopsy in Cancer Diagnostics: Market Segmentation
By Sample Type
• Blood
• Urine
By Technique
• Next Generation Sequencing
• Polymerase Chain Reaction
By Biomarker Type
• Circulating tumor DNA (ctDNA)
• Circulating free DNA (cfDNA)
• Circulating tumor cells (CTCs)
• Others
By End User
• Hospitals
• Clinics
• Diagnostic Centers
Liquid Biopsy in Cancer Diagnostics: Market Dynamics
Market Drivers
• Increase in disposable income which has led to more people opting for aesthetic surgeries.
• The rising number of cases of breast cancer worldwide which is a contributing factor in the growing demand for liquid biopsy in cancer diagnostics.
Market Barriers
• High cost of surgeries and post-surgical complications.
• Adverse events and product recalls.
Liquid Biopsy in Cancer Diagnostics: Market Analysis
This segment illustrates the market of liquid biopsy in cancer diagnostics across the 7MM and how the market is expected to rise in the study period (2018 to 2026), at a significant CAGR.
KOL Views
To keep up with the market trends, we take KOLs and SME’s opinion working in liquid biopsy in cancer diagnostics domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or liquid biopsy in cancer diagnostics market trend. This will support the clients in making informed business decisions by identifying the overall scenario of the market and the unmet needs.
Scope of the Report
• The report covers the descriptive overview of liquid biopsy in cancer diagnostics, explaining its applications, advantages, and limitations, etc.
• Additionally, an all-inclusive account of the currently available liquid biopsy in cancer diagnostics is provided, which will have an impact on the future market of liquid biopsy in cancer diagnostics.
• A detailed review of liquid biopsy in cancer diagnostics market; historical and forecasted market size is included in the report, covering devices outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the liquid biopsy in cancer diagnostics market.
Report Highlights
• The report covers descriptive overview of the liquid biopsy in cancer diagnostics, explaining its applications, working mechanism, etc.
• The report is a comprehensive account of marketed devices present in the liquid biopsy in cancer diagnostics market.
• The report also reviews the detailed historical and forecasted liquid biopsy in cancer diagnostics market, including assessing the outreach in 7 MM.
• The report helps in developing business strategies by understanding trends shaping and driving the liquid biopsy in cancer diagnostics market.
Liquid Biopsy in Cancer Diagnostics Report Key Strengths
• 6 Years Forecast
• 7MM Coverage
• Competitive Landscape
• PEST Analysis
• Market Size
Liquid Biopsy in Cancer Diagnostics Report Assessment
• Marketed Product profiles
• Key Products and Key Players
• Market Drivers and Barriers
• Market Forecast
• KOL’S views
Key Questions
Market Insights:
• What was the liquid biopsy in cancer diagnostics market share (%) distribution in 2018 and how it will look like in 2026?
• What will be the liquid biopsy in cancer diagnostics total market size as well as market size by devices across the 7MM during the forecast period (2018–2026)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest liquid biopsy in cancer diagnostics market size during the forecast period (2018–2026)?
• At what CAGR, the liquid biopsy in cancer diagnostics market is expected to grow in the 7MM during the forecast period (2018–2026)?
• What will be the liquid biopsy in cancer diagnostics market outlook across the 7MM during the forecast period (2018–2026)?
• What will be the liquid biopsy in cancer diagnostics market growth till 2026 and what will be the resultant market size in the year 2026?
• How will the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
Competitive Landscape:
• What are the current devices available in the liquid biopsy in cancer diagnostics market?
• What are the liquid biopsy in cancer diagnostics available in the market, their product description, regulatory milestones, product development activities, research and development activities etc.?
• How many key players are developing liquid biopsy in cancer diagnostics?
• What are the key collaborations (Industry–Industry), mergers and acquisitions, licensing activities related to the liquid biopsy in cancer diagnostics?
• What are the key designations that have been granted for the current liquid biopsy in cancer diagnostics?
• What are the 7MM countries historical and forecasted market of liquid biopsy in cancer diagnostics?
'
1. Key Insights
2. Executive Summary of Liquid Biopsy in Cancer Diagnostics
3. Liquid Biopsy in Cancer Diagnostics: Background and Overview
3.1. Introduction
3.2. Types of Liquid Biopsy in Cancer Diagnostics
3.3. Advantages of Liquid Biopsy in Cancer Diagnostics
3.4. Disadvantages of Liquid Biopsy in Cancer Diagnostics
4. Liquid Biopsy in Cancer Diagnostics: Regulatory Scenario
5. Liquid Biopsy in Cancer Diagnostics: Reimbursement Scenario
6. Company Profiles
6.1. Lucence
6.1.1. Company Overview
6.1.2. Product Portfolio
6.1.2.1. Product description
6.1.2.2. Regulatory Milestones
6.1.2.3. Research and Development
6.1.2.4. Product Development Activities
6.2. Guardant Health
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.2.1. Product description
6.2.2.2. Regulatory Milestones
6.2.2.3. Research and Development
6.2.2.4. Product Development Activities
More Companies in the final report…
7. Liquid Biopsy in Cancer Diagnostics: Competitive Analysis
8. KOL Views
9. Liquid Biopsy in Cancer Diagnostics: Market Analysis in 7MM
9.1. Liquid Biopsy in Cancer Diagnostics: Market Analysis in 7MM by Sample Type (2018–2026)
9.2. Liquid Biopsy in Cancer Diagnostics: Market Analysis in 7MM by Technique (2018–2026)
9.3. Liquid Biopsy in Cancer Diagnostics: Market Analysis in 7MM by Biomarker Type (2018–2026)
9.4. Liquid Biopsy in Cancer Diagnostics: Market Analysis in 7MM by End User (2018–2026)
10. Country-Wise Market size of Liquid Biopsy in Cancer Diagnostics in 7MM (2018–2026)
10.1. Market size of Liquid Biopsy in Cancer Diagnostics in the United States
10.1.1. Liquid Biopsy in Cancer Diagnostics: Market Analysis in the United States by Sample Type (2018–2026)
10.1.2. Liquid Biopsy in Cancer Diagnostics: Market Analysis in the United States by Technique (2018–2026)
10.1.3. Liquid Biopsy in Cancer Diagnostics: Market Analysis in the United States by Biomarker Type (2018–2026)
10.1.4. Liquid Biopsy in Cancer Diagnostics: Market Analysis in the United States by End User (2018–2026)
10.2. Market size of Liquid Biopsy in Cancer Diagnostics in Germany
10.2.1. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Germany by Sample Type (2018–2026)
10.2.2. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Germany by Technique (2018–2026)
10.2.3. Liquid Biopsy in Cancer Diagnostics: Market Analysis in the United States by Biomarker Type (2018–2026)
10.2.4. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Germany by End User (2018–2026)
10.3. Market size of Liquid Biopsy in Cancer Diagnostics in France
10.3.1. Liquid Biopsy in Cancer Diagnostics: Market Analysis in France by Sample Type (2018–2026)
10.3.2. Liquid Biopsy in Cancer Diagnostics: Market Analysis in France by Technique (2018–2026)
10.3.3. Liquid Biopsy in Cancer Diagnostics: Market Analysis in France by Biomarker Type (2018–2026)
10.3.4. Liquid Biopsy in Cancer Diagnostics: Market Analysis in France by End User (2018–2026)
10.4. Market size of Liquid Biopsy in Cancer Diagnostics in Spain
10.4.1. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Spain by Sample Type (2018–2026)
10.4.2. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Spain by Technique (2018–2026)
10.4.3. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Spain by Biomarker Type (2018–2026)
10.4.4. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Spain by End User (2018–2026)
10.5. Market size of Liquid Biopsy in Cancer Diagnostics in Italy
10.5.1. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Italy by Sample Type (2018–2026)
10.5.2. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Italy by Technique (2018–2026)
10.5.3. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Italy by Biomarker Type (2018–2026)
10.5.4. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Italy by End User (2018–2026)
10.6. Market size of Liquid Biopsy in Cancer Diagnostics in UK
10.6.1. Liquid Biopsy in Cancer Diagnostics: Market Analysis in UK by Sample Type (2018–2026)
10.6.2. Liquid Biopsy in Cancer Diagnostics: Market Analysis in UK by Technique (2018–2026)
10.6.3. Liquid Biopsy in Cancer Diagnostics: Market Analysis in UK by Biomarker Type (2018–2026)
10.6.4. Liquid Biopsy in Cancer Diagnostics: Market Analysis in UK by End User (2018–2026)
10.7. Market size of Liquid Biopsy in Cancer Diagnostics in Japan
10.7.1. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Japan by Sample Type (2018–2026)
10.7.2. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Japan by Technique (2018–2026)
10.7.3. Liquid Biopsy in Cancer Diagnostics: Market Analysis in UK by Biomarker Type (2018–2026)
10.7.4. Liquid Biopsy in Cancer Diagnostics: Market Analysis in Japan by End User (2018–2026)
11. Market Dynamics
11.1. Market Drivers
11.2. Market Barriers
12. PEST Analysis
13. Conclusion and Future Perspective
14. Appendix
14.1. Bibliography
14.2. Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
Table 1: Competitive Analysis
Table 2: Liquid Biopsy in Cancer Diagnostics Market Analysis in the 7MM (2018–2026)
Table 3: Liquid Biopsy in Cancer Diagnostics Market Analysis in the 7MM by Sample Type (2018–2026)
Table 4: Liquid Biopsy in Cancer Diagnostics Market Analysis in the 7MM by Technique (2018–2026)
Table 5: Liquid Biopsy in Cancer Diagnostics Market Analysis in the 7MM by Biomarker Type (2018–2026)
Table 6: Liquid Biopsy in Cancer Diagnostics Market Analysis in the 7MM by End User (2018–2026)
Table 7: Liquid Biopsy in Cancer Diagnostics United States Market Analysis (2018–2026)
Table 8: Liquid Biopsy in Cancer Diagnostics Market Analysis in the US by Sample Type (2018-2026)
Table 9: Liquid Biopsy in Cancer Diagnostics Market Analysis in the US by Technique (2018-2026)
Table 10: Liquid Biopsy in Cancer Diagnostics Market Analysis in the US by Biomarker Type (2018–2026)
Table 11: Liquid Biopsy in Cancer Diagnostics Market Analysis in the US by End User (2018-2026)
Table 12: Liquid Biopsy in Cancer Diagnostics Germany Market Analysis (2018–2026)
Table 13: Liquid Biopsy in Cancer Diagnostics Market Analysis in Germany by Sample Type (2018-2026)
Table 14: Liquid Biopsy in Cancer Diagnostics Market Analysis in Germany by Technique (2018-2026)
Table 15: Liquid Biopsy in Cancer Diagnostics Market Analysis in Germany by Biomarker Type (2018–2026)
Table 16: Liquid Biopsy in Cancer Diagnostics Market Analysis in Germany by End User (2018-2026)
Table 17: Liquid Biopsy in Cancer Diagnostics France Market Analysis (2018–2026)
Table 18: Liquid Biopsy in Cancer Diagnostics Market Analysis in France by Sample Type (2018-2026)
Table 19: Liquid Biopsy in Cancer Diagnostics Market Analysis in France by Technique (2018-2026)
Table 20: Liquid Biopsy in Cancer Diagnostics Market Analysis in France by Biomarker Type (2018–2026)
Table 21: Liquid Biopsy in Cancer Diagnostics Market Analysis in France by End User (2018-2026)
Table 22: Liquid Biopsy in Cancer Diagnostics Spain Market Analysis (2018–2026)
Table 23: Liquid Biopsy in Cancer Diagnostics Market Analysis in Spain by Sample Type (2018-2026)
Table 24: Liquid Biopsy in Cancer Diagnostics Market Analysis in Spain by Technique (2018-2026)
Table 25: Liquid Biopsy in Cancer Diagnostics Market Analysis in Spain by Biomarker Type (2018–2026)
Table 26: Liquid Biopsy in Cancer Diagnostics Market Analysis in Spain by End User (2018-2026)
Table 27: Liquid Biopsy in Cancer Diagnostics Italy Market Analysis (2018–2026)
Table 28: Liquid Biopsy in Cancer Diagnostics Market Analysis in Italy by Sample Type (2018-2026)
Table 29: Liquid Biopsy in Cancer Diagnostics Market Analysis in Italy by Technique (2018-2026)
Table 30: Liquid Biopsy in Cancer Diagnostics Market Analysis in Italy by Biomarker Type (2018–2026)
Table 31: Liquid Biopsy in Cancer Diagnostics Market Analysis in Italy by End User (2018-2026)
Table 32: Liquid Biopsy in Cancer Diagnostics United Kingdom Market Analysis (2018–2026)
Table 33: Liquid Biopsy in Cancer Diagnostics Market Analysis in the UK by Sample Type (2018-2026)
Table 34: Liquid Biopsy in Cancer Diagnostics Market Analysis in the UK by Technique (2018-2026)
Table35: Liquid Biopsy in Cancer Diagnostics Market Analysis in the UK by Biomarker Type (2018–2026)
Table 36: Liquid Biopsy in Cancer Diagnostics Market Analysis in the UK by End User (2018-2026)
Table 37: Liquid Biopsy in Cancer Diagnostics Japan Market Analysis (2018–2026)
Table 38: Liquid Biopsy in Cancer Diagnostics Market Analysis in Japan by Sample Type (2018-2026)
Table 39: Liquid Biopsy in Cancer Diagnostics Market Analysis in Japan by Technique (2018-2026)
Table 40: Liquid Biopsy in Cancer Diagnostics Market Analysis in Japan by Biomarker Type (2018–2026)
Table 41: Liquid Biopsy in Cancer Diagnostics Market Analysis in Japan by End User (2018-2026)
Guardant Health, Qiagen, F. Hoffmann-La Roche AG, Inviata, ArcherDx, Bio-Techne., Resolution Bioscience & LabCorp., Personal Genome Diagnostics., Helio Health, Lucence, Foundation medicine Inc.., Biocept, Sysmex Corporation, Veridex LLC and Biodesix, among others.
